A Baltimore company is working on an alternative to cannabis that will offer another medication option for those struggling with chronic pain or anxiety.
MIRA1a Therapeutics is currently preparing its namesake product, "MIRA1a," for the U.S. Food and Drug Administration approval process next year. The drug binds to the brain's cannabinoid receptors — the same parts of the brain impacted by medical cannabis — in order to to replicate the anti-inflammatory and painkilling properties of cannabis,…
